2015
DOI: 10.3389/fmicb.2015.00459
|View full text |Cite
|
Sign up to set email alerts
|

The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics

Abstract: The paramyxovirus family includes major human and animal pathogens, including measles virus, mumps virus, and human respiratory syncytial virus (RSV), as well as the emerging zoonotic Hendra and Nipah viruses. In the U.S., RSV is the leading cause of infant hospitalizations due to viral infectious disease. Despite their clinical significance, effective drugs for the improved management of paramyxovirus disease are lacking. The development of novel anti-paramyxovirus therapeutics is therefore urgently needed. P… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
35
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 47 publications
(37 citation statements)
references
References 155 publications
(240 reference statements)
2
35
0
Order By: Relevance
“…According to current models of replication/ transcription of negative strand non-segmented RNA viruses, the template RNA is covered by N protein (NP) and only 2-3 NP molecules are assumed to be displaced simultaneously at the site of transcription, giving access to not more than 30 nucleotides. 18,19 Yet, at present it cannot be excluded that larger regions of RNA become transiently accessible during EBOV transcriptional initiation (e.g. by VP30 displacing NP), also taking into account that the leader promoter is bipartite in EBOV, and thus more extended, than in vesicular stomatitis virus (VSV) or respiratory syncytial virus (RSV); furthermore, Ebola VP30 is an exceptionally large and unique viral transcription factor within the Mononegavirales, which leaves the possibility open that temporary RNA accessibilities are different in the EBOV system.…”
Section: Discussionmentioning
confidence: 99%
“…According to current models of replication/ transcription of negative strand non-segmented RNA viruses, the template RNA is covered by N protein (NP) and only 2-3 NP molecules are assumed to be displaced simultaneously at the site of transcription, giving access to not more than 30 nucleotides. 18,19 Yet, at present it cannot be excluded that larger regions of RNA become transiently accessible during EBOV transcriptional initiation (e.g. by VP30 displacing NP), also taking into account that the leader promoter is bipartite in EBOV, and thus more extended, than in vesicular stomatitis virus (VSV) or respiratory syncytial virus (RSV); furthermore, Ebola VP30 is an exceptionally large and unique viral transcription factor within the Mononegavirales, which leaves the possibility open that temporary RNA accessibilities are different in the EBOV system.…”
Section: Discussionmentioning
confidence: 99%
“…The hRSV RNA-dependent RNA complex (RdRp) constitutes a virus-specific target with specific protein-protein interactions that have not all been investigated in detail (7). It uses the nonsegmented single-stranded negative sense RNA genome of hRSV as a template.…”
mentioning
confidence: 99%
“…Following cell entry, the genomic RNPs are released into the cytosol and the encapsidated viral RNA serves as a template of the RdRP complex for both transcription and replication [5]. Transcription begins at the 3′ end of the genome and viral genes are transcribed in the 3′ to 5′direction with a sequential “stop–start” mechanism.…”
Section: Genome and Lifecyclementioning
confidence: 99%
“…The virion of MeV is a pleomorphic or spherical particle with a diameter ranging from 120 to 1000 nm and has two major structural components: one is the helical ribonucleoprotein (RNP) core formed by the association of the nucleoprotein (N), phosphoprotein (P) and large protein (L) with the viral genome, the other is the cellular membrane-derived lipid envelope surrounding the RNP core [1,4,5]. The active RNP complex is responsible for initiating primary transcription after cell entry as well as counteracting the host interferon (IFN) signaling pathway [5,6,7].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation